Tags

Type your tag names separated by a space and hit enter

Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors?
Gastroenterol Clin Biol. 2009 Jun; 33 Suppl 3:S228-34.GC

Abstract

Inflammatory bowel diseases are the result of an abnormal immune response to environmental factors including the intestinal microbiota. Epithelial and immune cells of the intestinal mucosa recognise specific bacterial molecules via Toll like and NOD like receptors and this interaction modulates the inflammatory response (activation of the NF-kappaB pathway). It is thus rational to try treatments which could modify the intestinal microbiota i.e. antibiotics, new substrates (prebiotics) or new micro-organisms (probiotics). We review the literature on existing evidence for the efficacy of probiotic strains or combinations in patients with pouchitis (good evidence), ulcerative colitis (fair evidence), and Crohn's disease (no evidence at the present time). We also discuss the mechanisms of action, the use of microbial agents as pharmacological vectors, the development of genetically modified probiotics (including a clinical pilot trial in patients with Crohn's disease), and safety issues.

Authors+Show Affiliations

AP-HP, Hôpital Lariboisière, Medicosurgical Department of Digestive Diseases, Laboratoire de Biologie EA 3199, CNAM & University Diderot-Paris 7, Paris, France. philippe.marteau@lrb.aphp.frNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20117346

Citation

Marteau, P, et al. "Bacteriotherapy for Inflammatory Bowel Disease: Therapeutic Tool And/or Pharmacological Vectors?" Gastroenterologie Clinique Et Biologique, vol. 33 Suppl 3, 2009, pp. S228-34.
Marteau P, Sokol H, Dray X, et al. Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors? Gastroenterol Clin Biol. 2009;33 Suppl 3:S228-34.
Marteau, P., Sokol, H., Dray, X., & Seksik, P. (2009). Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors? Gastroenterologie Clinique Et Biologique, 33 Suppl 3, S228-34. https://doi.org/10.1016/S0399-8320(09)73158-6
Marteau P, et al. Bacteriotherapy for Inflammatory Bowel Disease: Therapeutic Tool And/or Pharmacological Vectors. Gastroenterol Clin Biol. 2009;33 Suppl 3:S228-34. PubMed PMID: 20117346.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors? AU - Marteau,P, AU - Sokol,H, AU - Dray,X, AU - Seksik,P, PY - 2010/2/2/entrez PY - 2010/2/2/pubmed PY - 2010/12/18/medline SP - S228 EP - 34 JF - Gastroenterologie clinique et biologique JO - Gastroenterol. Clin. Biol. VL - 33 Suppl 3 N2 - Inflammatory bowel diseases are the result of an abnormal immune response to environmental factors including the intestinal microbiota. Epithelial and immune cells of the intestinal mucosa recognise specific bacterial molecules via Toll like and NOD like receptors and this interaction modulates the inflammatory response (activation of the NF-kappaB pathway). It is thus rational to try treatments which could modify the intestinal microbiota i.e. antibiotics, new substrates (prebiotics) or new micro-organisms (probiotics). We review the literature on existing evidence for the efficacy of probiotic strains or combinations in patients with pouchitis (good evidence), ulcerative colitis (fair evidence), and Crohn's disease (no evidence at the present time). We also discuss the mechanisms of action, the use of microbial agents as pharmacological vectors, the development of genetically modified probiotics (including a clinical pilot trial in patients with Crohn's disease), and safety issues. SN - 0399-8320 UR - https://www.unboundmedicine.com/medline/citation/20117346/Bacteriotherapy_for_inflammatory_bowel_disease:_therapeutic_tool_and/or_pharmacological_vectors L2 - https://linkinghub.elsevier.com/retrieve/pii/S0399-8320(09)73158-6 DB - PRIME DP - Unbound Medicine ER -